Funding for this research was provided by:
Bristol-Myers Squibb (N/A)
Text and Data Mining valid from 2018-12-01
Received: 17 September 2018
Accepted: 14 November 2018
First Online: 6 December 2018
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation Guidelines for Good Clinical Practice and local regulations. Schulman Associates Institutional Review Board or Independent Ethics Committees approved the protocol, consent form and any other written information provided to patients or their legal representatives.
: Not applicable.
: VS reports receiving consulting fees from AbbVie, Amgen Corporation, AstraZeneca, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Corrona, Crescendo/Myriad Genetics, EMD Serono, Genentech/Roche, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi and UCB. EA, TL, AJ, SB and HAA are employees of Bristol-Myers Squibb and report holding stock in Bristol-Myers Squibb. PJM reports receiving consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Janssen, Lilly, Merck, Novartis, Pfizer, Sun, UCB and Zynerba; and speaker fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Novartis, Pfizer and UCB.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.